Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy.
a dominant-negative effect and that this assay is sensitive to a reduction in wild-type TP53 or ATM below a critical level.
The important practical question is whether this functional assay provides additional prognostic information compared to standard fluorescence in situ hybridization analysis for TP53 and ATM loss. Seven out of 47 patients in this study had TP53 dysfunction and either an ATM or TP53 mutation without loss of the other allele. All had progressive disease requiring early treatment. Those with category 1 dysfunction failed to respond to alkylating agents or fludarabine. Although six of these cases had other risk factors for progressive disease including unmutated VH genes or use of the VH 3-21 gene, these data would support a screening strategy able to detect TP53 and ATM mutations as well as loss.
TP53 and especially ATM mutational analysis remains the province of specialized laboratories and will detect both clinically important and unimportant mutations. The etoposide/nutlin-3a functional assay provides a rapid and widely applicable screening method for clinically relevant mutations of both genes and also, potentially, for other defects in the doublestranded DNA damage repair pathway. 2 NPM1 mutations are mutually exclusive of recurrent genetic abnormalities and characteristically associate with de novo AML. 1, 2 We report for the first time a patient who developed AML with NPM1 mutation 6 years after a JAK2-V617F þ primary myelofibrosis (PMF).
OG
In May 2000, a 61-year-old woman was referred to the Haematology Institute of University 'La Sapienza', Rome, with a high platelet count (733 000 mm À3 ) and a slight splenomegaly; the white blood cell (WBC) count and the haemoglobin level were normal. A bone marrow biopsy showed an increased number of dysplastic megakaryocytes that were arranged in clusters of 5-10 cells (Figure 1a) . At the Gomori staining, there was a marked bone marrow fibrosis; iron deposits were not visible. Based on these findings PMF was diagnosed. Retrospective analysis of the JAK2 gene status on paraffin sections 3 from the initial trephine biopsy detected the JAK2-V617F mutation in about 25% of haemopoietic cells (Figures 1b and c) . Cytogenetic studies could not be performed due to the lack of metaphases. The patient was not treated until September 2000 when, due to a rise in platelets (1 236 000 mm À3 ), she was started on hydroxyurea (1 g daily, 5 days per week), which provided optimal control of the platelet count.
In April 2006, the patient presented with anaemia (9.5 g per 100 ml) and a low WBC count (1700 mm À3 ). Bone marrow aspirate and biopsy showed 490% myeloid blasts (M1 type) and residual dysplastic megakaryocytes (Figure 2a ). Cytogenetic analysis of marrow AML cells showed a normal karyotype; BCR/ ABL rearrangement as well as FLT3-ITD and FLT3-D835 mutations was absent. Microelectronic chip analysis 4 detected a low JAK2-V617F allelic ratio of about 5%, which strongly suggested that only a small fraction of the cells harboured the JAK2-V617F mutation (Figure 2b ). Immunohistological analysis of the bone marrow biopsy showed marked infiltration (490%) by leukaemic cells that were positive for CD68 (KP1) and myeloperoxidase ( Figure 3 , top left), but negative for CD68 macrophage-restricted (PG-M1) and CD34 ( Figure 3 , top right). Notably, all AML cells showed an aberrant NPM cytoplasmic expression ( Figure 3 , bottom left), while the dysplastic megakaryocytes belonging to the PMF clone displayed nucleus-restricted NPM positivity ( Figure 3 , bottom left, arrows). Cytoplasmic NPM is the distinguishing immunohistological hallmark of AML with NPM1 mutations, 1,2 and indeed, mutational analysis detected a NPM1 mutation, that is, type A mutation 1 ( Figure 3 , bottom, right). Given these histological, immunohistological and molecular findings, an NPMc þ AML occurring in the setting of a JAK2-V617F þ PMF was diagnosed.
In May 2006, the patient received chemotherapy according to the MICE schedule (mitoxantrone, ARA-C, etoposide). One month later, a bone marrow aspirate and biopsy showed a complete haematological remission. Two consolidation cycles with the mini-ICE schedule (idarubicin, ARA-C, etoposide) were completed in August 2006 and, at the last control (November 2007), the patient remains in complete haematological remission and the number of platelets is presently within the normal Figure 1) . At that time, a JAK2-V617F mutation was detected in about 40% of marrow haemopoietic cells.
In our patient, the previously unreported association of NPM1 and JAK2-V617F mutations raises the important issue of how the newly developed NPMc þ AML was linked with the preceding chronic myeloproliferative disorder (MPD). Using immunohistochemistry on paraffin sections, we first determined whether NPM1 mutations were present in the bone marrow when the JAK2-V617F þ PMF was first diagnosed in the year 2000. Notably, all haematopoietic cells showed a nucleus-restricted NPM positivity (not shown), which is fully predictive of a wildtype NPM1 gene. 1, 5 This concurs with previous reports that chronic MPDs do not carry NPM1 mutations. 1 We then determined whether NPMc þ AML cells carried a JAK2-V617F mutation. For this purpose, groups of 30-50 myeloid leukaemic cells (selected according to the morphological appearance and glycophorin negativity) were microdissected from frozen sections of an undecalcified bone marrow trephine taken at time of AML diagnosis using a pulsed ultraviolet laser (Olympus Micro_beam with PALM 'inside' technology; Olympus, Tokyo, Japan) and laser catapulted into DNase-free tubes coated with 1% bovine serum albumin/10 mM Tris, as previously described 6 ( Figure 4 , top and middle). JAK2 mutational analysis (performed as previously described 7 ) did not detect a JAK2-V617F mutation in the two pools of cells analysed (Figure 4, bottom) . Therefore, the present case is an example of an NPM1-mutated/JAK2-V617FÀ AML in a JAK2-V617F þ PMF.
The finding of a JAK2-V617F negativity in the leukaemic cells of our case is in keeping with previous reports that AML developing in JAK2-V617F þ chronic MPDs frequently carries a wild-type JAK2 gene. 8, 9 Since our patient's leukaemic cells harboured an NPM1 mutation in the absence of JAK2-V617F, the NPM1 mutation appeared to be the leukaemogenic event. This is consistent with the observation that the JAK2-V617F mutation is very rare in de novo AML (about 1%), 10 suggesting that it plays a minor role in the pathogenesis of AML.
There are at least three possible explanations for the origin of a JAK2-V617FÀ AML in a JAK2-V617F þ chronic MPD. 8 In our patient, AML could have arisen from an heterozygous JAK2-V617F clone with reversion to a wild-type JAK2 genotype through mitotic recombination. Such a mechanism was excluded in two cases that were available for study. 8, 9 Thus, derivation of AML from a pre-JAK2-V617FÀ clone or de novo origin from a normal haemopoietic stem cell appears more likely in our patient.
We used a polymorphism in the X-chromosomal gene IDS to assess clonality by X-chromosome inactivation pattern analysis. Bone marrow cells at diagnosis of NPMc þ AML (490% blast cells) and at time of complete haematological and molecular remission were scored for the IDS polymorphism using an allelespecific PCR, as previously described. 7 The same X chromosome was inactivated in the AML and PMF clones ( Figure 5 ). These results are compatible with a common origin of the NPMc þ AML and the JAK2-V617F þ MPD clone. However, Letters to the Editor since there is a 0.5 probability of the same X chromosome being inactivated, the AML could have also arisen de novo.
Indeed, a number of reasons suggest a de novo origin of the NPMc þ AML in our patient with JAK2-V617F þ PMF. NPM1 mutations have not been detected in PMF cases in their chronic phase. 11 With the exception of the present case, cytoplasmic mutated NPM was not detected in any of the 45 AML secondary to chronic MPDs we have investigated to date by mutational analysis and/or immunohistochemistry (myeloid blastic transformation of BCR-ABL þ chronic myeloid leukaemia n ¼ 12; AML following essential thrombocythaemia n ¼ 8; AML following polycythaemia vera n ¼ 9; AML following PMF n ¼ 9; AML following chronic myelomonocytic leukaemia n ¼ 6; AML following MPD/myelodysplasia n ¼ 1), which is in keeping with the close association of NPM1 mutations with de novo AML. 1, 2 Moreover, our patient's leukaemic cells showed features that were typical of de novo NPMc þ AML, that is, normal karyotype and CD34 negativity, and clearly differed from AML secondary to chronic MPDs which are usually CD34 þ and have abnormal karyotype. Another evidence in favour of a de novo NPMc þ AML was the patient's excellent response to induction therapy. She is currently alive and in complete haematological and molecular remission (Supplementary Figure 1) , 1.5 years after the initial diagnosis of AML. This is consistent with the finding that her leukaemic cells were NPM1-mutated/FLT3-ITDÀ, a Analysis of clonality using X-chromosome inactivation pattern. Allele-specific PCR assay for the C/T polymorphism in the Xchromosomal gene IDS was performed with fluorescently labelled primers. The chromatograms are shown. The T-specific primer was extended by three non-homologous nucleotides to allow separation of the PCR products by size. (a) Bone marrow (BM) cDNA at AML diagnosis. (b) AML in remission. cDNA from bone marrow cells at diagnosis and in remission, as well as cDNA from granulocytes (GRA) in remission showed inactivation of the same X chromosome. DNA from granulocytes demonstrates that the patient was heterozygous for the IDS polymorphism.
genotype that has been associated with good prognosis in AMLs with normal karyotype. 2 In contrast, AML secondary to chronic MPDs is usually characterized by a poor prognosis. This clinical course is even more remarkable, considering that the patient was over 67 years old when the AML diagnosis was carried out, an age associated with a poor prognostic likelihood.
NPMc þ AML is unlikely to have been related to the previous hydroxyurea therapy, as cytoplasmic-mutated NPM is rarely associated with therapy-related AML. 1 Moreover, the leukaemogenic role of hydroxyurea in chronic MPDs remains controversial. 12 In conclusion, we report for the first time on a case of NPMc þ AML developing in a JAK2-V617F þ PMF. Although no definitive conclusion can be drawn about the cell of origin of AML in our patient, the finding that the blast cells lacked JAK2-V617F and displayed all distinctive features of NPMc þ AML suggests that the leukaemic transformation may have occurred de novo in a normal stem cell. Recognition of cases such as the one described in this study is clinically important since AMLs developing in chronic MPDs may be molecularly heterogeneous and their prognoses may vary according to the underlying genetic lesion.
